



AMENDMENT TRANSMITTAL LETTER (Large Entity)				Docket No. 3364/1/US	
Applicant(s):					
Application No. 09/839,424	Filing Date April 20, 2001	Examiner Binta M. Robinson	Customer No. 26648	Group Art Unit 1625	Confirmation No. 1761
Invention: 2-FLUOROBENZENSULFONYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION					
COMMISSIONER FOR PATENTS:					
Transmitted herewith is an amendment in the above-identified application.					
The fee has been calculated and is transmitted as shown below.					
CLAIMS AS AMENDED					
	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST # PREV. PAID FOR	NUMBER EXTRA CLAIMS PRESENT	RATE	ADDITIONAL FEE
TOTAL CLAIMS	28 -	113 =	0 x	\$18.00	\$0.00
INDEP. CLAIMS	4 -	10 =	0 x	\$88.00	\$0.00
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					\$0.00
TOTAL ADDITIONAL FEE FOR THIS AMENDMENT					\$0.00
<input checked="" type="checkbox"/> No additional fee is required for amendment. <input type="checkbox"/> Please charge Deposit Account No. _____ in the amount of _____ <input type="checkbox"/> A check in the amount of _____ to cover the filing fee is enclosed. <input checked="" type="checkbox"/> The Director is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account 19-1025 <input checked="" type="checkbox"/> Any additional filing fees required under 37 C.F.R. 1.16. <input checked="" type="checkbox"/> Any patent application processing fees under 37 CFR 1.17. <input type="checkbox"/> Payment by credit card. Form PTO-2038.					
WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.					
 Signature Philip B. Polster II, Reg. No. 43,864 Pharmacia Corporation of Pfizer Inc. P.O. Box 1027 Chesterfield, Missouri 63006 314.274.9094			Dated: November 22, 2004		
CC:			I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on November 22, 2004 (Date)  Signature of Person Mailing Correspondence Linda K. Cooper Typed or Printed Name of Person Mailing Correspondence		



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT:	David L. Brown)	GROUP ART UNIT:	1625
)		
SERIAL NO.:	09/839,424)	CONFIRMATION NO.:	1761
)		
EXAMINER:	Binta M. Robinson)	ATTORNEY DOCKET NO.:	3364/1/US
)		
FILED:	04/20/2001)		
)		
TITLE:	2-FLUOROBENZENSULFONYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION			

CERTIFICATE OF MAILING

I hereby certify that this communication and any recited enclosures are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on November 22, 2004.


Linda K. Cooper

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RESPONSE TO OFFICE ACTION

Sir:

This letter is in response to the Office Action of September 2, 2004, having a Shortened Statutory Period for Response that was set to expire on December 2, 2004.

Appln. No. 09/839,424 PFE REFERENCE NO. 3364/1/US
Amendment dated 22 November 2004
Reply to Office action dated 2 September 2004

The Applicants believe that this response is timely made, however, please charge any appropriate fees to Deposit Account No 19-1025. Please amend the above-identified application as follows:

Amendments to the Claims are reflected in the listing of claims that begins on page 3 of this paper.

Remarks/Arguments begin on page 21 of this paper.